PPA
JUNO

Parametric Portfolio Associates’s Juno Therapeutics, Inc. JUNO Stock Holding History

Parametric Portfolio Associates’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-63,372
Closed -$2.9M – 3995
2017
Q4 		$2.9M Buy
63,372
+9,648
+18% +$481K ﹤0.01% 2344
2017
Q3 		$2.41M Buy
53,724
+9,975
+23% +$340K ﹤0.01% 2464
2017
Q2 		$1.31M Buy
43,749
+3,923
+10% +$96.8K ﹤0.01% 2824
2017
Q1 		$884K Buy
39,826
+18,713
+89% +$401K ﹤0.01% 2927
2016
Q4 		$398K Buy
21,113
+6,109
+41% +$149K ﹤0.01% 3294
2016
Q3 		$450K Buy
15,004
+2,519
+20% +$78.4K ﹤0.01% 3225
2016
Q2 		$480K Buy
12,485
+5,245
+72% +$218K ﹤0.01% 3214
2016
Q1 		$276K Sell
7,240
-5,465
-43% -$190K ﹤0.01% 3636
2015
Q4 		$559K Buy
+12,705
New +$630K ﹤0.01% 3179
2015
Q3 		– Sell
-4,209
Closed -$224K – 3430
2015
Q2 		$224K Buy
+4,209
New +$223K ﹤0.01% 3715

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Parametric Portfolio Associates's JUNO Position: Q1 2018 in Review

Parametric Portfolio Associates sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 63,372 shares — an estimated $2.9M sold.

Parametric Portfolio Associates first reported a position in JUNO in Q2 2015 and held it in 10 quarters. The position peaked at $2.9M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Parametric Portfolio Associates reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Parametric Portfolio Associates sold 63,372 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $2.9M.
  • Parametric Portfolio Associates first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 10 quarters.
  • Parametric Portfolio Associates's Juno Therapeutics, Inc. position peaked at $2.9M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Parametric Portfolio Associates's 13F filing for Q1 2018, filed 14 May 2018.